I'm John Fort. You're listening to CNBC's Tech Check. Our show is live weekdays at 11 a.m. Eastern. Listen in.

Happy Wednesday. Welcome to Tech Check. I'm John Fort with Carl Kingtonia and Deirdrebosa. Today,

tech has an attention span problem. We're going to tell you why historically low short interest is leaving few winners this week.

And then Kathy Wood explains her potential new investing strategy,

ARC on steroids.

Plus, meet the fund manager who's taking the other side of every one of the trades she makes.

That's coming up later in the hour.

And finally, pop the hood.

This stock is having serious trouble why shares of Robin Hood

are down nearly 30% in just the last month, Dee. Well, we start today's feed with what's

become a multi-day sell-off in tech stocks. The NASDAQ lower once again by about a quarter of 1%

as yields rise. The stock's hardest hit have been those smaller high multiple growth stocks.

We've been talking

about all week. Peloton, Crowdstrike, Octa, down double digits over the last week.

Arc Invest, Kathy Wood was on Squawk Box earlier this morning, defending her investments

and even touting a new strategy she's testing that she says is, quote, like Arc on steroids.

What we would be doing is shorting stocks that are in the big benchmarks.

And when we get into a risk off situation, what happens is portfolio managers and analysts

generally run back to those stocks, get closer to their benchmarks.

And they dump our stocks, which are either small parts of

benchmarks or not in benchmarks. Great opportunity for us, as we have experienced during these

last few days, to pick up on those stocks because it's simply a risk-off move to get closer to

...